1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol, 2008, 65(1): 8-20.
|
3. |
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet, 2014, 383(9927): 1490-1502.
|
4. |
Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, et al. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep, 2018, 39(6): 2455-2472.
|
5. |
Wu XX, Yue GG, Dong JR, et al. Actein inhibits tumor growth and metastasis in HER2-positive breast tumor bearing mice via suppressing AKT/mTOR and Ras/Raf/MAPK signaling pathways. Front Oncol, 2020, 10: 854.
|
6. |
Guo X, Zhou N, Chen Z, et al. Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer, 2020, 23(4): 614-626.
|
7. |
胥润, 杜正贵. HER-2 阳性乳腺癌抗 HER-2 双靶向治疗的研究进展. 中国普外基础与临床杂志, 2021, 28(4): 544-550.
|
8. |
Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol, 2018, 29(5): 1108-1119.
|
9. |
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8: 16.
|
10. |
Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One, 2014, 9(5): e98528.
|
11. |
Stahler A, Heinemann V, Neumann J, et al. Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. Anticancer Drugs, 2017, 28(7): 717-722.
|
12. |
Meng X, Wang R, Huang Z, et al. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis. Cancer Sci, 2014, 105(7): 818-824.
|
13. |
Zhang X, Wu J, Wang L, et al. HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China. PeerJ, 2020, 8: e8602.
|
14. |
Wang XY, Zheng ZX, Sun Y, et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol, 2019, 11(4): 335-347.
|
15. |
Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer, 2014, 111(10): 1977-1984.
|
16. |
Liu F, Ren C, Jin Y, et al. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Virchows Arch, 2020, 476(3): 391-398.
|
17. |
Nam SK, Yun S, Koh J, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One, 2016, 11(3): e0151865.
|
18. |
Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3 256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol, 2016, 238(4): 562-570.
|
19. |
Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med, 2011, 135(1): 55-62.
|
20. |
Pyo JS, Kang G, Park K. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis. Int J Biol Markers, 2016, 31(4): e389-e394.
|
21. |
Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol, 2017, 35(4): 446-464.
|
22. |
Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol, 2015, 28(11): 1481-1491.
|
23. |
Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist, 2019, 24(10): 1395-1402.
|
24. |
Laurent-Puig P, Balogoun R, Cayre A, et al. ERBB2 alterations a new prognostic biomarker in stage Ⅲ colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol, 2016, 27(6): 149-206.
|
25. |
Sun SJ, Lin Q, Sun Q, et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Cancer Res Ther, 2016, 12(1): 323-333.
|
26. |
Wu SW, Ma CC, Li WH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol, 2015, 10: 144.
|
27. |
Li C, Liu DR, Ye LY, et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B, 2014, 15(6): 582-589.
|
28. |
Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol, 2010, 41(11): 1577-1585.
|
29. |
Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol, 2014, 25(10): 1995-2001.
|
30. |
Siena S, Sartore-Bianchi A, Trusolino L, et al. Final results of the HERACLES trial in HER2 amplified colorectal cancer. Ann Oncol, 2016, 27(Supplement 4): iv39-iv54.
|
31. |
Wei Q, Zhang Y, Gao J, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer, 2019, 18(3): 175-182.
|
32. |
Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer, 2006, 6: 123.
|
33. |
Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precision Oncology, 2019, 3(3): 1-13.
|
34. |
Dong Z, Kong L, Wan Z, et al. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Sci Rep, 2019, 9(1): 16894.
|
35. |
Li QH, Wang YZ, Tu J, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf), 2020, 8(3): 179-191.
|
36. |
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol, 2019, 20(4): 518-530.
|
37. |
陈功. 2019 年结直肠癌治疗进展盘点. 肿瘤综合治疗电子杂志, 2020, 1(6): 89-90.
|